Dr. Reddy''s Lab
Ticker >

Dr. Reddy''s Lab share price

Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  162k   1k   156

5622.15
+193.05 (3.56%)
NSE: Today, 12:54 PM

Price Summary

Today's High

₹ 5630

Today's Low

₹ 5453.25

52 Week High

₹ 5989.7

52 Week Low

₹ 4175.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 93768.9 Cr.

Enterprise Value

₹ 93173.9 Cr.

No. of Shares

16.68 Cr.

P/E

24.99

P/B

4.27

Face Value

₹ 5

Div. Yield

0.74 %

Book Value (TTM)

₹  1317.19

CASH

₹ 645.8 Cr.

DEBT

₹ 50.8 Cr.

Promoter Holding

26.69 %

EPS (TTM)

₹  225

Sales Growth

17.75%

ROE

13.57 %

ROCE

18.91%

Profit Growth

60.97 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 32 Indices.

NIFTYEQWGT

NIFTY50 Equal Weight
23584.1
  228.149999999998 (0.976838878315789%)

NIFTY100WEIGHT

Nifty100 Equal Weight
23201.05
  233.899999999998 (1.01841107843157%)

NIFTY

Nifty 50
19664.2
  140.650000000001 (0.720412015232896%)

NIFTY100

Nifty 100
19602.85
  151.199999999997 (0.777311950400073%)

NIFTYLOWVOL

Nifty Low Volatility 50
18522.15
  58.8900000000031 (0.318957757189153%)

NIFTY500

Nifty 500
17311.9
  141.450000000001 (0.823799026816419%)

NIFTYPHARMA

Nifty Pharma
15466
  442.85 (2.94778392014989%)

NT100LOW30

Nifty100 Low Volatility 30
15055.65
  148.1 (0.993456335883502%)

NT100ALP30

NIFTY100 Alpha 30
12446.6
  115.040000000001 (0.932890891338989%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
11888.15
  109.799999999999 (0.932218859178069%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
11832.1
  98.7000000000007 (0.841188402338622%)

NIFTY200

Nifty 200
10523.1
  86.9500000000007 (0.833161654441539%)

NIFTYMFG

Nifty Manufacturing
9810.5
  136.200000000001 (1.40785379820763%)

NIFTYHEALTH

Nifty Healthcare Index
9738.65
  262.549999999999 (2.77065459418959%)

NIFTYTOTALMCAP

Nifty Total Market index
9712.85
  78.8999999999996 (0.818978715895335%)

NIFTY500VAL50

NIFTY500 Value 50
9072.76
  36.4400000000005 (0.403261504683328%)

NIFTY100ESG

NIFTY100 ESG
3730.5
  22.9499999999998 (0.619007161063223%)

BSE HC

S&P Bse Healthcare
28544.04
  664.870000000003 (2.38482709492429%)

BSE500

S&P Bse 500
27438.41
  224.880000000001 (0.826353655699941%)

SNSX50

S&P Bse Sensex50
20617.4
  149.720000000001 (0.7314947272969%)

BSE100

S&P Bse 100
20148.15
  155.75 (0.779046037494258%)

BSE200

S&P Bse 200
8622.9
  71.3799999999992 (0.834705409096848%)

LMI250

S&P Bse 250 LargeMidCap
8172.17
  67.2600000000002 (0.829867327336142%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
8045.61
  -84.4200000000001 (-1.03837255213081%)

ALLCAP

S&P Bse Allcap
7969.75
  65.3699999999999 (0.827009835053483%)

LRGCAP

S&P Bse LargeCap
7472.05
  56.1100000000006 (0.756613456958943%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
7138.49
  53.0999999999995 (0.749429459775675%)

CARBONEX

S&P Bse Carbonex
3279.49
  26.2799999999997 (0.80781750947525%)

SPBSLVIP

S&P Bse Low Volatility
1400.13
  15.0800000000002 (1.08876935850692%)

MFG

S&P Bse Manufacturing
806.79
  8.44999999999993 (1.05844627602274%)

S&PDIVSTABLE

S&P Bse Dividend Stability
725.31
  7.2299999999999 (1.00685160427807%)

ESG100

S&P Bse 100 ESG Index
321.86
  2.53000000000003 (0.792283844299013%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year17.75%
3 Year12.7%
5 Year12.63%

Profit Growth

1 Year60.97%
3 Year-3.83%
5 Year35.74%

ROE%

1 Year13.57%
3 Year12.17%
5 Year13.65%

ROCE %

1 Year18.91%
3 Year16.13%
5 Year15.89%

Debt/Equity

0.0025

Price to Cash Flow

18.56

Interest Cover Ratio

229.757396449704

CFO/PAT (5 Yr. Avg.)

1.36377310244985

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 26.69 0
Mar 2023 26.7 0
Dec 2022 26.7 0
Sep 2022 26.71 0
Jun 2022 26.71 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 2154.6 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 229.757396449704.
  • The Company has been maintaining an effective average operating margins of 22.3764283862017% in the last 5 years.
  • Company’s PEG ratio is 0.411155359513579.
  • The company has an efficient Cash Conversion Cycle of 52.6004927286632 days.
  • Company has a healthy liquidity position with current ratio of 3.08171723314638.
  • The company has a good cash flow management; CFO/PAT stands at 1.36377310244985.

 Limitations

  • The company has shown a poor profit growth of -3.83148540578682% for the Past 3 years.
  • The company has shown a poor revenue growth of 12.6987113843859% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 3630.6 4880.3 3897.6 4554 5437.3
Total Expenditure 3051.1 3077.5 3222.5 3492.9 3209.6
Operating Profit 579.5 1802.8 675.1 1061.1 2227.7
Other Income 403.4 118 51.4 114.8 233.6
Interest 9.8 1.7 2.8 2.6 4.5
Depreciation 221.5 226.2 238.8 236.7 237.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 751.6 1692.9 484.9 936.6 2219.6
Tax 252.1 576.6 160.3 264.2 580.2
Profit After Tax 499.5 1116.3 324.6 672.4 1639.4
Adjusted EPS (Rs) 30.02 67.09 19.48 40.36 98.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 10625.5 11850.4 13349.1 14405.2 16962.5
Total Expenditure 8360.9 8980.8 10212.3 11811.1 12747.7
Operating Profit 2264.6 2869.6 3136.8 2594.1 4214.8
Other Income 273.5 743.2 801.1 482 591.3
Interest 56.8 47.8 46.7 38 16.9
Depreciation 780.6 789.2 835 814.3 923.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 1700.7 2775.8 3056.2 2223.8 3866
Tax 423.4 -161.9 869.8 600.6 1253.2
Net Profit 1277.3 2937.7 2186.4 1623.2 2612.8
Adjusted EPS (Rs.) 76.95 176.76 131.39 97.55 156.83

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 83 83.1 83.2 83.2 83.3
Total Reserves 12601.1 15108.8 16900.5 18253 20390.9
Borrowings 345.4 19.3 17.7 19.7 28.6
Other N/C liabilities 138.7 -528.8 -186.9 75.2 432.3
Current liabilities 3079.3 4180.5 4560.3 6045.1 4439.7
Total Liabilities 16247.5 18862.9 21374.8 24476.2 25374.8
Assets
Net Block 4682.7 4433.9 5844.3 6150.5 7206.7
Capital WIP 400.1 384.1 877.1 1186.4 899.1
Intangible WIP 0 27.7 23.7 13.9 13.9
Investments 1819.1 3367.1 3392.2 3018.7 3248.6
Loans & Advances 407 542 293.2 409.8 324.6
Other N/C Assets 5.4 1.4 0.1 200 0
Current Assets 8933.2 10106.7 10944.2 13496.9 13681.9
Total Assets 16247.5 18862.9 21374.8 24476.2 25374.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1700.7 2775.8 3056.2 2223.8 3866
Adjustment 958.1 681.8 273.3 845.1 1045.8
Changes in Assets & Liabilities 342.1 -1141.5 632.7 -1241.4 923.7
Tax Paid -238.8 -476.9 -448 -488.8 -782.7
Operating Cash Flow 2762.1 1839.2 3514.2 1338.7 5052.8
Investing Cash Flow -546.5 -1689.2 -1453.6 -1990.1 -3403.1
Financing Cash Flow -2223.1 -224.1 -794.3 505.5 -2696.9
Net Cash Flow -7.5 -74.1 1266.3 -145.9 -1047.2

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 26.71 26.71 26.70 26.70 26.69
anuradha gunupati 0.01 0.01 0.01 0.01 0.01
aps trust 20.64 20.63 - 20.62 20.62
gunupati venkateswara pra... - - - 1.53 1.53
kallam satish reddy huf - 3.32 - 3.32 3.32
samrajyam reddy kallam 0.67 0.67 0.67 0.67 0.67
satish reddy kallam 0.54 0.54 0.54 0.54 0.54
aps trust (trustees: g. v... - - 20.62 - -
gunupati venkateswara pra... - - 1.53 - -
kallam satish reddy huf (... - - 3.32 - -
gunupati venkateswara pra... - 1.53 - - -
gunupati venkateswara pra... 1.53 - - - -
k.satish reddy (huf) 3.32 - - - -
PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
investors 73.29 73.29 73.30 73.30 73.31
first sentier investors i... - 2.20 2.20 2.20 2.20
government of singapore - 1.86 1.36 1.30 1.24
hdfc life insurance compa... - - 1.03 1.04 1.04
hdfc trustee company ltd.... 1.19 1.16 1.36 1.62 1.77
investor education and pr... - 0.14 0.14 0.14 0.14
life insurance corporatio... 6.04 7.58 8.95 9.79 9.72
nps trust-a/c hdfc pensio... 1.57 1.80 1.89 1.94 2.13
sbi-etf nifty 50 2.63 2.63 1.57 1.54 1.68
government pension fund g... 1.13 1.01 1.06 1.01 -
icici prudential sensex i... 1.87 1.46 1.05 1.02 -
nippon life india trustee... - - 1.16 1.04 -
aditya birla sun life tru... 1.90 1.56 - - -
icici prudential life ins... 1.57 1.14 - - -
kuwait investment authori... - 1.14 - - -
first senter investors ic... 2.20 - - - -
government of singapore -... 2.03 - - - -
iepf 0.14 - - - -
uti-mastershare unit sche... 1.24 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Reddy's Laboratories gets nod to incorporate Wholly-owned Subsidiary28 Sep 2023, 3:28PM Dr. Reddy’s Laboratories informs about information on newspaper publication 5 Sep 2023, 10:01AM Dr. Reddy's Laboratories launches Saxagliptin and Metformin Hydrochloride Extended-Release Tablets10 Aug 2023, 2:50PM Dr. Reddy's Laboratories reports 18% rise in Q1 consolidated net profit26 Jul 2023, 6:05PM Dr. Reddy's Lab - Quaterly Results26 Jul 2023, 4:02PM Dr. Reddy's Lab - Quaterly Results26 Jul 2023, 4:02PM Dr. Reddy's Lab - Quaterly Results26 Jul 2023, 4:02PM USFDA completes PAI, GMP inspection at Dr. Reddy's Laboratories’ Andhra Pradesh facility20 Jul 2023, 10:07AM Dr. Reddy's Laboratories to invest in O2 Renewable Energy IX17 Jul 2023, 10:00AM Dr. Reddy’s proposed rituximab biosimilar application accepted for review by USFDA13 Jul 2023, 11:29AM Dr Reddy's Laboratories eyeing to enhance presence in emerging segments like nutraceuticals11 Jul 2023, 3:30PM Dr. Reddy’s selects AWS as preferred cloud provider11 Jul 2023, 10:41AM Dr Reddy’s forays into child nutrition space with launch of gummies 7 Jul 2023, 10:59AM Dr. Reddy's Laboratories enters into trade generics business in India23 Jun 2023, 3:06PM Dr.Reddy's Laboratories informs about disclosure17 Jun 2023, 1:10PM USFDA completes GMP inspection at Dr. Reddy's API manufacturing facility in Bollaram17 Jun 2023, 11:18AM Dr.Reddy's Laboratories informs about press release14 Jun 2023, 5:03PM Dr. Reddy’s Laboratories informs about press release5 Jun 2023, 9:51AM USFDA completes inspection at Dr. Reddy's formulations manufacturing facility in Srikakulam13 May 2023, 10:27AM Dr. Reddy’s Laboratories informs about audio recording of earnings call11 May 2023, 11:52AM Dr. Reddy's Laboratories reports around 10-fold jump in Q4 consolidated net profit 10 May 2023, 6:12PM Dr. Reddy's Lab - Quaterly Results10 May 2023, 5:10PM Dr. Reddy's Lab - Quaterly Results10 May 2023, 5:10PM Dr. Reddy's Lab - Quaterly Results10 May 2023, 5:10PM Dr. Reddy's Laboratories gets one observations from USFDA for Hyderabad facility6 May 2023, 10:52AM Dr. Reddy's Laboratories launches Regadenoson Injection in U.S. market5 May 2023, 3:50PM Dr Reddy's Laboratories informs about press release 21 Apr 2023, 4:37PM Dr. Reddy's Laboratories launches Treprostinil Injection in U.S. market21 Apr 2023, 12:00PM DR. Reddy's Laboratories informs about allotment of ESOP21 Mar 2023, 1:19PM Dr Reddy's signs deal to divest certain non-core brands in dermatology to Eris Lifesciences16 Mar 2023, 4:17PM Dr Reddy's Laboratories’ arm recalling 4,320 bottles of Tacrolimus Capsules in US8 Mar 2023, 11:29AM Dr. Reddy’s Laboratories informs about investors conferences 28 Feb 2023, 10:44AM Dr. Reddy’s Laboratories’ arm inks pact to acquire Mayne Pharma’s U.S. generic prescription product portfolio 27 Feb 2023, 12:29PM Dr. Reddy’s Laboratories informs about press release27 Feb 2023, 9:42AM Dr. Reddy's Laboratories included in Bloomberg GEI 2023 for sixth consecutive year9 Feb 2023, 10:30AM Dr. Reddy's Laboratories informs about press release 27 Jan 2023, 3:07PM Dr. Reddy’s launches Difluprednate Ophthalmic Emulsion in US market27 Jan 2023, 12:30PM Dr. Reddy's Laboratories reports 75% rise in Q3 consolidated net profit27 Jan 2023, 10:40AM Dr.Reddy's Laboratories informs about disclosure25 Jan 2023, 4:29PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy's Lab - Quaterly Results25 Jan 2023, 4:09PM Dr. Reddy’s completes full set of clinical studies of rituximab biosimilar for filing in U.S., Europe20 Jan 2023, 2:40PM Dr. Reddy’s Laboratories informs about press release20 Jan 2023, 9:48AM Dr Reddy's reduces price of cardiovascular drug ‘Cidmus’19 Jan 2023, 10:50AM Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer Products13 Jan 2023, 6:08PM Dr. Reddy's inks pact with Theranica 11 Jan 2023, 4:09PM Dr. Reddy’s Laboratories informs about disclosure 29 Dec 2022, 9:28AM Dr. Reddy's Laboratories completes Phase 1 study of proposed biosimilar of Tocilizumab20 Dec 2022, 11:51AM Dr.Reddy's Laboratories informs about press release19 Dec 2022, 1:49PM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 5052.8 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.0025 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was 60.7726854751656 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 24.8477523949889 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 13.5654467386959 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Dr. Reddy''s Lab

Dr. Reddy''s Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Dr. Reddy's Laboratories Ltd. is a leading Indian pharmaceutical company that specializes in the production of generic drugs and active pharmaceutical ingredients. In this article, we will provide a comprehensive analysis of Dr. Reddy's Laboratories Ltd.'s stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Dr. Reddy''s Laboratories Ltd. Share Price:

Dr. Reddy's Laboratories Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s share price and identify any trends or patterns. The company's share price has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Balance Sheet:

Dr. Reddy's Laboratories Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and inventory, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s balance sheet and identify any red flags. The company's balance sheet has been strong over the past few years, reflecting the company's ability to generate cash and manage its liabilities.

Dr. Reddy''s Laboratories Ltd. Annual Report:

Dr. Reddy's Laboratories Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Dividend:

Dr. Reddy's Laboratories Ltd. pays dividends to its shareholders. The company has a consistent dividend policy and pays dividends regularly. Long-term investors should consider this when evaluating Dr. Reddy's Laboratories Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Dr. Reddy''s Laboratories Ltd. Quarterly Results:

Dr. Reddy's Laboratories Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Dr. Reddy''s Laboratories Ltd. Stock Price:

The stock price of Dr. Reddy's Laboratories Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Dr. Reddy's Laboratories Ltd.'s stock price and identify potential buying opportunities. The stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. News:

Keeping up to date with the latest news about Dr. Reddy's Laboratories Ltd. is important for investors. Our website provides the latest news about Dr. Reddy's Laboratories Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Dr. Reddy''s Laboratories Ltd. Concall:

Dr. Reddy's Laboratories Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Dr. Reddy's Laboratories Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Dr. Reddy''s Laboratories Ltd. Transcripts:

Transcripts of Dr. Reddy's Laboratories Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Investor Presentations:

Dr. Reddy's Laboratories Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Dr. Reddy's Laboratories Ltd.'s promoters include Dr. Reddy's family and entities related to them. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Dr. Reddy's Laboratories Ltd. are relatively stable, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Shareholders:

Dr. Reddy's Laboratories Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Dr. Reddy's Laboratories Ltd. is diverse, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

X